Skip to content

Technology
Pipeline
About Us
News
Investors
Contact

Technology
Pipeline
About Us
News
Investors
Contact

Virtual Key Opinion Leader Event to Discuss NS002 for the Treatment of Anaphylaxis

By lsc-webmaster / June 10, 2026

Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)

Zacks Life Sciences Investor Forum

Science

Technology
Pipeline
NS003 Ondansetron
NS002 Epinephrine
NS001 Naloxone
Publications

Company

About us
Leadership
Board of Directors
Advisory Board
Contact

Investors

Investors Overview
Press Releases
Events
SEC Filings
Company Reports
Corporate Governance
Stock Information
Investor FAQs

© 2026 Nasus Pharma All rights reserved

Accessibility Statement
Cookies Policy
Privacy Policy
Terms And Conditions Of Use

Scroll to Top